Araclon 
Araclon Biotech, a Grifols company, presented the results of its clinical validation study of ABtest-MS in populations with mild cognitive impairment, and of its ABvac40 vaccine regarding its impact on the progression of Alzheimer’s disease (AD) and Cerebral Amyloid Angiopathy (CAA) at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD … Read more
We are thrilled to announce our participation in the upcoming AD/PD 2025 Congress in Vienna (April 1-5) // Join us at AD/PD2025 Congress in Vienna (April 1-5) This hybrid event will unite experts and leaders from the health, neuroscience, and biotechnology sectors to discuss the latest advancements in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, … Read more
What is ABvac40? ABvac40 is a vaccine developed to prevent Alzheimer’s disease from its earliest stages. Phase 2 clinical studies have shown promising results, indicating that the vaccine is safe and capable of generating a strong and sustained immune response over time. In addition, some patients have experienced some cognitive benefits, although these findings need … Read more
